18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Extreme Phenotypes With Identical Mutations: Two Patients With Same Non-sense NHEJ1 Homozygous Mutation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cernunnos/XLF deficiency is a rare primary immunodeficiency classified within the DNA repair defects. Patients present with severe growth retardation, microcephaly, lymphopenia and increased cellular sensitivity to ionizing radiation. Here, we describe two unrelated cases with the same non-sense mutation in the NHEJ1 gene showing significant differences in clinical presentation and immunological profile but a similar DNA repair defect.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining.

          DNA nonhomologous end-joining (NHEJ) is a predominant pathway of DNA double-strand break repair in mammalian cells, and defects in it cause radiosensitivity at the cellular and whole-organism levels. Central to NHEJ is the protein complex containing DNA Ligase IV and XRCC4. By searching for additional XRCC4-interacting factors, we identified a previously uncharacterized 33 kDa protein, XRCC4-like factor (XLF, also named Cernunnos), that has weak sequence homology with XRCC4 and is predicted to display structural similarity to XRCC4. We show that XLF directly interacts with the XRCC4-Ligase IV complex in vitro and in vivo and that siRNA-mediated downregulation of XLF in human cell lines leads to radiosensitivity and impaired NHEJ. Furthermore, we establish that NHEJ-deficient 2BN cells derived from a radiosensitive and immune-deficient patient lack XLF due to an inactivating frameshift mutation in its gene, and that reintroduction of wild-type XLF into such cells corrects their radiosensitivity and NHEJ defects. XLF thus constitutes a novel core component of the mammalian NHEJ apparatus.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly.

            DNA double-strand breaks (DSBs) occur at random upon genotoxic stresses and represent obligatory intermediates during physiological DNA rearrangement events such as the V(D)J recombination in the immune system. DSBs, which are among the most toxic DNA lesions, are preferentially repaired by the nonhomologous end-joining (NHEJ) pathway in higher eukaryotes. Failure to properly repair DSBs results in genetic instability, developmental delay, and various forms of immunodeficiency. Here we describe five patients with growth retardation, microcephaly, and immunodeficiency characterized by a profound T+B lymphocytopenia. An increased cellular sensitivity to ionizing radiation, a defective V(D)J recombination, and an impaired DNA-end ligation process both in vivo and in vitro are indicative of a general DNA repair defect in these patients. All five patients carry mutations in the Cernunnos gene, which was identified through cDNA functional complementation cloning. Cernunnos/XLF represents a novel DNA repair factor essential for the NHEJ pathway.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              ATM Damage Response and XLF Repair Factor are Functionally Redundant In Joining DNA Breaks

              Classical non-homologous DNA end-joining (C-NHEJ) is a major mammalian DNA double strand break (DSB) repair pathway. Deficiencies for C-NHEJ factors, such as XRCC4, abrogate lymphocyte development, owing to a strict requirement for C-NHEJ to join V(D)J recombination DSB intermediates1,2. The XRCC4-like factor (XLF) is mutated in certain immunodeficient human patients and has been implicated in C-NHEJ3,4,5,6. Yet, XLF-deficient mice have relatively normal lymphocyte development and their lymphocytes support normal V(D)J recombination5. The Ataxia Telangiectasia-Mutated protein (“ATM”) detects DSBs and activates DSB responses by phosphorylating substrates including histone H2AX7. However, ATM-deficiency causes only modest V(D)J recombination and lymphocyte developmental defects, and H2AX-deficiency does not measurably impact these processes7,8,9. Here, we show that XLF, ATM, and H2AX all have fundamental roles in processing and joining ends during V(D)J recombination; but that these roles have been masked by unanticipated functional redundancies. Thus, combined ATM/XLF-deficiency nearly blocks mouse lymphocyte development due inability to process and join chromosomal V(D)J recombination DSB intermediates. Combined XLF and ATM deficiency also severely impairs C-NHEJ, but not alternative end-joining, during IgH class switch recombination. Redundant ATM and XLF functions in C-NHEJ are mediated via ATM kinase activity and are not required for extra-chromosomal V(D)J recombination, suggesting a role for chromatin-associated ATM substrates. Correspondingly, conditional H2AX inactivation in XLF-deficient pro-B lines leads to V(D)J recombination defects associated with marked degradation of unjoined V(D)J ends, revealing that H2AX indeed has a role in this process.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                07 January 2019
                2018
                : 9
                : 2959
                Affiliations
                [1] 1Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, 12 de Octubre Health Research Institute (imas12) , Madrid, Spain
                [2] 2Hospital 12 de Octubre Health Research Institute (imas12) , Madrid, Spain
                [3] 3Pediatric Hematology and Oncology Unit, University Hospital Virgen de la Salud , Toledo, Spain
                [4] 4Pediatric Hematology and Oncology Unit, University Hospital Miguel Servet , Zaragoza, Spain
                [5] 5Immunodeficiencies Unit, Pediatrics, University Hospital 12 octubre , Madrid, Spain
                [6] 6Complutense University School of Medicine , Madrid, Spain
                [7] 7Department of Immunology, University Hospital 12 Octubre , Madrid, Spain
                Author notes

                Edited by: Andrew R. Gennery, Newcastle University, United Kingdom

                Reviewed by: Silvia Clara Giliani, Università degli Studi di Brescia, Italy; John Bernard Ziegler, Sydney Children's Hospital, Australia

                *Correspondence: Luis Ignacio Gonzalez-Granado luisignacio.gonzalez@ 123456salud.madrid.org

                This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology

                †These authors have contributed equally to this work and share senior authorship

                Article
                10.3389/fimmu.2018.02959
                6330288
                30666249
                a627b4ea-6f63-446d-8c87-01c8212e4691
                Copyright © 2019 Recio, Dominguez-Pinilla, Perrig, Rodriguez Vigil-Iturrate, Salmón-Rodriguez, Martinez Faci, Castro-Panete, Blas-Espada, López-Nevado, Ruiz-Garcia, Chaparro-García, Allende and Gonzalez-Granado.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 05 October 2018
                : 30 November 2018
                Page count
                Figures: 2, Tables: 4, Equations: 0, References: 22, Pages: 8, Words: 4355
                Categories
                Immunology
                Original Research

                Immunology
                xlf/cernunnos,nhej1 mutation,dna repair,severe combined immunodeficiency,lymphomagenesis,radiosensitive scid (rs-scid)

                Comments

                Comment on this article